Trial Profile
A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate Lebrikizumab (MILR1444A) in Adult Patients With Asthma Who Are Not Taking Inhaled Corticosteroids (MOLLY).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Dec 2016
Price :
$35
*
At a glance
- Drugs Lebrikizumab (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Acronyms MOLLY
- Sponsors Genentech
- 17 Mar 2012 Actual initiation date changed from 1 Nov 2009 to 16 Oct 2009 as reported by European Clinical Trials Database.
- 12 Jul 2011 Actual end date (Feb 2011) added as reported by ClinicalTrials.gov.
- 12 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.